{
    "clinical_study": {
        "@rank": "102577", 
        "arm_group": {
            "arm_group_label": "NovaCross, CTO", 
            "arm_group_type": "Experimental", 
            "description": "assess the safety and technical feasibility, deployment and withdrawal characteristics of the NovaCross\u2122 micro-catheter during an interventional coronary angioplasty procedure  and evaluating the CTO penetration rate."
        }, 
        "brief_summary": {
            "textblock": "This is a prospective, non-randomized, first-in-man investigational study, to assess the\n      safety and technical feasibility, deployment and withdrawal characteristics of the\n      NovaCross\u2122 micro-catheter during an interventional coronary angioplasty procedure  and\n      evaluating the CTO penetration rate.\n\n      Each study subject/patient will have a total of one (1) procedure performed for this study."
        }, 
        "brief_title": "A Prospective, First in Man Study to Evaluate the Safety and Performance of the NovaCross\u2122 Micro-catheter", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Total Occlusion of Coronary Artery", 
        "detailed_description": {
            "textblock": "To be filled later"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Adult aged 25-80\n\n          2. Patient understands and has signed the study informed consent form.\n\n          3. Patient has an angiographic documented Chronic Total Occlusion (i.e. >3 months\n             occlusion duration) showing distal TIMI flow 0.\n\n          4. Suitable candidate for non-emergent, coronary angioplasty\n\n          5. Documented coronary angiography preceding the PCI reveals at least one CTO lesion\n             situated in a non-infarct related coronary artery or its side branches with the\n             following characteristics:\n\n               1. Thrombolysis in Myocardial Infarction (TIMI) 0 flow for at least 90 days;\n\n               2. Satisfactory distal vessel visualization\n\n               3. CTO should be amenable to percutaneous treatment and must be located in a\n                  coronary vessel with a reference diameter of at least 2 millimeters.\n\n               4. CTO refractory to a minimum of 10 minutes of conventional guide wire attempt.\n\n          6. Body Mass Index (BMI) < 40\n\n          7. Left ventricle ejection fraction > 25%\n\n        For the purpose of this trial, a CTO is defined as a 100% luminal narrowing without\n        antegrade flow or with antegrade or retrograde filling through collateral vessels.\n\n        -\n\n        Exclusion Criteria:\n\n          -  1. Patient unable to give informed consent. 2. Current participation in another study\n             with any investigational drug or device.\n\n             3. Patient is known or suspected not to tolerate the contrast agent. 4. Aorto-ostial\n             CTO location (Ostial bifurcation origins may be considered), SVG CTO and in-stent\n             CTOs.\n\n             5. Intolerance to aspirin or Clopidogrel or Prasugrel or Ticagrelor medications 6.\n             Appearance of a fresh thrombus or intraluminal filling defects. 7. Recent major\n             cerebrovascular event (history of stroke or TIA within 1 month) 8. Cardiac\n             intervention within 4 weeks of the procedure 9. Renal insufficiency (serum creatinine\n             of > 2.3mg/dl) 10. Active gastrointestinal bleeding 11. Active infection or fever\n             that may be due to infection 12. Life expectancy < 2 years due to other illnesses 13.\n             Significant anemia (hemoglobin < 8.0 mg / dl) 14. Severe uncontrolled systemic\n             hypertension (> 240 mmHg within 1 month of procedure )\n\n             15. Severe electrolyte imbalance 16. Congestive heart failure [New York Heart\n             Association (NYHA) Class III\\IV] ,CSA Class IV.\n\n             17. Unstable angina requiring emergent percutaneous trans-luminal coronary\n             angioplasty (PTCA) or coronary artery bypass graft (CABG) 18. Recent myocardial\n             infarction (MI) (within the past two weeks) 19. Uncontrolled diabetes >2 serum\n             glucose concentrations of >350 mg/dl within 7 days.\n\n             20. Participation in another investigational protocol 21. Unwillingness or inability\n             to comply with any protocol requirements 22. Pregnant or nursing 23. Extensive prior\n             dissection from a coronary  guidewire use 24. Drug abuse or alcoholism. 25. Patients\n             under custodial care. 26. Bleeding diathesis or coagulation disorder; 27. Kawasaki's\n             disease or other vasculitis."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "25 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01978860", 
            "org_study_id": "NT-C200-02 Rev 01", 
            "secondary_id": "HTA6696"
        }, 
        "intervention": {
            "arm_group_label": "NovaCross, CTO", 
            "description": "evaluate the safety and performance of the NovaCross\u2122 micro-catheter in respect to providing additional guidewire support that is expected to allow easier crossing of Chronic Total Occlusion (CTO) lesions in coronary arteries.", 
            "intervention_name": "NovaCross, CTO", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "CABG  Coronary artery bypass grafting", 
            "CTO Chronic Total Occlusion", 
            "PCI Percutaneous coronary intervention", 
            "MACE Major adverse cardiovascular event(s)", 
            "MI Myocardial infarction"
        ], 
        "lastchanged_date": "November 7, 2013", 
        "location": {
            "contact": {
                "email": "dalit@nitiloop.com", 
                "last_name": "Dalit - Carmon-Doron, Msc/ Eng", 
                "phone": "+972525611156"
            }, 
            "contact_backup": {
                "last_name": "Orly - Maor, Msc"
            }, 
            "facility": {
                "address": {
                    "city": "Jerusalem", 
                    "country": "Israel", 
                    "zip": "XXXX"
                }, 
                "name": "Hadasa Ei Karem"
            }, 
            "investigator": {
                "last_name": "Chaim Lotan, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Prospective, First in Man Study to Evaluate the Safety and Performance of the NovaCross\u2122 Micro-catheter in (CTO) Coronary Lesions", 
        "overall_contact": {
            "last_name": "Dalit"
        }, 
        "overall_official": {
            "affiliation": "Hadassah Ein Karem, Jerusalem Israel", 
            "last_name": "Chaim - Lotan, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: The Israel National Institute for Health Policy Research and Health Services Research", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": ". 30-day Lack of device-related Major Adverse Cardiac Event Rate (MACE) at the site of target coronary lesion and/or its proximal reference segment.\nTime Frame:", 
            "measure": "lack of device related major adverse event", 
            "safety_issue": "Yes", 
            "time_frame": "30 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01978860"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Nitiloop Ltd.", 
            "investigator_full_name": "Dalit Carmon-Doron", 
            "investigator_title": "COO", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "Maneuverability of the NovaCross \u2122 up to the occlusion and safe withdrawal.The ability to cross the lesion with a guidewire in the true lumen, effectively dilate the CTO lesion and place a coronary stent with residual lumen stenosis of less than 30% and restoring antegrade TIMI 3 flow.", 
            "measure": "Maneuverability of the NovaCross \u2122 up to the occlusion and safe withdrawal", 
            "safety_issue": "Yes", 
            "time_frame": "During Procedure"
        }, 
        "source": "Nitiloop Ltd.", 
        "sponsors": {
            "collaborator": {
                "agency": "Clinical Research Consultants, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Dalit Carmon-Doron", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}